Form 8-K - Current report:
SEC Accession No. 0001104659-25-015224
Filing Date
2025-02-19
Accepted
2025-02-19 17:02:20
Documents
13
Period of Report
2025-02-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm257101d1_8k.htm   iXBRL 8-K 25939
  Complete submission text file 0001104659-25-015224.txt   200967

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20250212_lab.xml EX-101.LAB 34240
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20250212_pre.xml EX-101.PRE 22361
4 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20250212.xsd EX-101.SCH 3018
15 EXTRACTED XBRL INSTANCE DOCUMENT tm257101d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 25641462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)